pf-03491390 and Hepatitis-C--Chronic

pf-03491390 has been researched along with Hepatitis-C--Chronic* in 1 studies

Other Studies

1 other study(ies) available for pf-03491390 and Hepatitis-C--Chronic

Article	Year
First-in-class pan caspase inhibitor developed for the treatment of liver disease. Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22 A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease. Topics: Adult; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Biological Availability; Caspase 3; Caspase Inhibitors; Cholestasis; Clinical Trials, Phase I as Topic; Half-Life; Hepatitis C, Chronic; Hepatocytes; Humans; Jurkat Cells; Liver; Liver Diseases; Mice; Pentanoic Acids; Rats; Structure-Activity Relationship	2005

Article

Year

First-in-class pan caspase inhibitor developed for the treatment of liver disease.

Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.

Topics: Adult; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Biological Availability; Caspase 3; Caspase Inhibitors; Cholestasis; Clinical Trials, Phase I as Topic; Half-Life; Hepatitis C, Chronic; Hepatocytes; Humans; Jurkat Cells; Liver; Liver Diseases; Mice; Pentanoic Acids; Rats; Structure-Activity Relationship

2005